Literature DB >> 16214922

Polymorphisms and haplotypes in the cytochrome P450 17A1, prolactin, and catechol-O-methyltransferase genes and non-Hodgkin lymphoma risk.

Christine F Skibola1, Paige M Bracci, Randi A Paynter, Matthew S Forrest, Luz Agana, Trevor Woodage, Karl Guegler, Martyn T Smith, Elizabeth A Holly.   

Abstract

Expression of prolactin and of prolactin and estrogen receptors in lymphocytes, bone marrow, and lymphoma cell lines suggests that hormonal modulation may influence lymphoma risk. Prolactin and estrogen promote the proliferation and survival of B cells, factors that may increase non-Hodgkin lymphoma risk, and effects of estrogen may be modified by catechol-O-methyltransferase (COMT), an enzyme that alters estrogenic activity. Cytochrome P450 17A1 (CYP17A1), a key enzyme in estrogen biosynthesis, has been associated with increased cancer risk and may affect lymphoma susceptibility. We studied the polymorphisms prolactin (PRL) -1149G>T, CYP17A1 -34T>C, and COMT 108/158Val>Met, and predicted haplotypes among a subset of participants (n = 308 cases, n = 684 controls) in a San Francisco Bay Area population-based non-Hodgkin lymphoma study (n = 1,593 cases, n = 2,515 controls) conducted from 1988 to 1995. Oral contraceptive and other hormone use also was analyzed. Odds ratios (OR) for non-Hodgkin lymphoma and follicular lymphoma were reduced for carriers of the PRL -1149TT genotype [OR, 0.64; 95% confidence interval (95% CI), 0.41-1.0; OR, 0.53; 95% CI, 0.26-1.0, respectively]. Diffuse large-cell lymphoma risk was increased for those with CYP17A1 polymorphisms including CYP17A1 -34CC (OR, 2.0; 95% CI, 1.1-3.5). ORs for all non-Hodgkin lymphoma and follicular lymphoma among women were decreased for COMT IVS1 701A>G [rs737865; variant allele: OR, 0.53; 95% CI, 0.34-0.82; OR, 0.42; 95% CI, 0.23-0.78, respectively]. Compared with never users of oral contraceptives, a 35% reduced risk was observed among oral contraceptive users in the total population. Reduced ORs for all non-Hodgkin lymphoma were observed with use of exogenous estrogens among genotyped women although 95% CIs included unity. These results suggest that PRL, CYP17A1, and COMT may be relevant genetic loci for non-Hodgkin lymphoma and indicate a possible role for prolactin and estrogen in lymphoma pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16214922     DOI: 10.1158/1055-9965.EPI-05-0343

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  15 in total

Review 1.  Host genetics in follicular lymphoma.

Authors:  James R Cerhan
Journal:  Best Pract Res Clin Haematol       Date:  2011-05-05       Impact factor: 3.020

2.  Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival.

Authors:  Xuesong Han; Tongzhang Zheng; Francine M Foss; Qing Lan; Theodore R Holford; Nathaniel Rothman; Shuangge Ma; Yawei Zhang
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

3.  Polymorphism of the extrapituitary prolactin promoter and systemic sclerosis.

Authors:  Markéta Fojtíková; Pavlína Cejková; Radim Bečvář; Jiří Vencovský; Jana Tomasová Studýnková; Marie Cerná
Journal:  Rheumatol Int       Date:  2009-12-19       Impact factor: 2.631

4.  Oral contraceptives, menopausal hormone therapy use and risk of B-cell non-Hodgkin lymphoma in the California Teachers Study.

Authors:  Yani Lu; Sophia S Wang; Jane Sullivan-Halley; Ellen T Chang; Christina A Clarke; Katherine D Henderson; Huiyan Ma; Lei Duan; James V Lacey; Dennis Deapen; Leslie Bernstein
Journal:  Int J Cancer       Date:  2010-12-08       Impact factor: 7.396

5.  A functional TNFRSF5 gene variant is associated with risk of lymphoma.

Authors:  Christine F Skibola; Alexandra Nieters; Paige M Bracci; John D Curry; Luz Agana; Danica R Skibola; Alan Hubbard; Nikolaus Becker; Martyn T Smith; Elizabeth A Holly
Journal:  Blood       Date:  2008-02-20       Impact factor: 22.113

6.  The role of estrogen receptor β in transplacental cancer prevention by indole-3-carbinol.

Authors:  Abby D Benninghoff; David E Williams
Journal:  Cancer Prev Res (Phila)       Date:  2013-02-27

7.  Urinary biomarkers suggest that estrogen-DNA adducts may play a role in the aetiology of non-Hodgkin lymphoma.

Authors:  Nilesh W Gaikwad; Li Yang; Dennis D Weisenburger; Julie Vose; Cheryl Beseler; Eleanor G Rogan; Ercole L Cavalieri
Journal:  Biomarkers       Date:  2009-11       Impact factor: 2.658

8.  Variants in hormone biosynthesis genes and risk of endometrial cancer.

Authors:  Sara H Olson; Irene Orlow; Sharon Bayuga; Camelia Sima; Elisa V Bandera; Katherine Pulick; Shameka Faulkner; Diana Tommasi; Daniel Egan; Pampa Roy; Homer Wilcox; Ali Asya; Ippolito Modica; Haider Asad; Robert Soslow; Ann G Zauber
Journal:  Cancer Causes Control       Date:  2008-04-25       Impact factor: 2.506

9.  Non-Hodgkin lymphoma in women: reproductive factors and exogenous hormone use.

Authors:  Jennifer S Lee; Paige M Bracci; Elizabeth A Holly
Journal:  Am J Epidemiol       Date:  2008-06-10       Impact factor: 4.897

Review 10.  Genetic susceptibility to lymphoma.

Authors:  Christine F Skibola; John D Curry; Alexandra Nieters
Journal:  Haematologica       Date:  2007-07       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.